Amide (CTX), ifosfamide (IFO), adriamycin (ADM), vincristine (VCR), vinblastine (VBL), etoposide (VP 16), valium (Vumon), carboplatin (CBP) and methotrexate (MTX) are commonly used chemotherapy drugs for small cell lung cancer. Because of cell heterogeneity, drug resistance and individual differences, the curative effect of non-small cell lung cancer is further limited. As the future research direction, cisplatin (DDP) is the most popular drug in the treatment of non-small cell lung cancer, and it is considered as a means to prolong the life of patients with stage ⅳ non-small cell lung cancer. It has almost become an indispensable common chemotherapy drug in the combined regimen of non-small cell lung cancer, and can also be used as radiotherapy sensitizer. In addition, other single drugs for non-small cell lung cancer with RR≥ 15% include IFO, VP 16, mitomycin (MMC), vinblastine amide (VDS), ADM, EPItope (epi) and vinblastine. Carboplatin is a commonly used drug to treat lung cancer, but the side effects of chemotherapy drugs will be great. It is suggested to use it with Yinmai lifesaving agent, which can resist various side effects in the process of chemotherapy, enhance the sensitivity of chemotherapy drugs, and thus reduce the number of chemotherapy.